


PHARMACEUTICAL 2022



Atea Pharmaceuticals Inc. Rank 5 of 466





PHARMACEUTICAL 2022



Atea Pharmaceuticals Inc. Rank 5 of 466



The relative strengths and weaknesses of Atea Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Atea Pharmaceuticals Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 97% points. The greatest weakness of Atea Pharmaceuticals Inc. is the variable Other Assets, reducing the Economic Capital Ratio by 1.8% points.

The company's Economic Capital Ratio, given in the ranking table, is 321%, being 243% points above the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	772,403
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	56,883
Liabilities, Non-Current	5,932
Other Assets	466
Other Compr. Net Income	0
Other Expenses	17,400
Other Liabilities	0
Other Net Income	0
Other Revenues	351,580
Property and Equipment	23
Research and Development	167,205
Selling, General and Administrative Expense	45,785

Output Variable	Value in 1000 USD
Assets	772,892
Liabilities	62,815
Expenses	230,390
Revenues	351,580
Stockholders Equity	710,077
Net Income	121,190
Comprehensive Net Income	121,190
Economic Capital Ratio	321%

